Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05894876 · ClinicalTrials.gov registry record
A Study of the Genetic Basis of Response to Growth Hormone Treatment in Children With Idiopathic Short Stature
A clinical trial, sponsored by Novo Nordisk A/S.
- Terminated
- Registry status
- 43
- Enrollment target
NCT05894876: Clinical Trial study, sponsored by Novo Nordisk A/S.
NCT05894876 is a clinical trial that was terminated before completion, run by Novo Nordisk A/S. The registered enrollment target is 43 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05894876 was terminated before completion, sponsored by Novo Nordisk A/S.
- TERMINATED
- Registry status
- 43 participants
- Enrollment target
Study Summary
The study doctor will collect information from participants with Idiopathic Short Stature, who were treated with growth hormone for at least a year when they were children, before they reached puberty. The word "Idiopathic" refers to "unknown cause", and as such the study participants have/had short stature with no identifiable medical cause. The purpose of the study is to identify differences in the genetic characteristics of participants who responded well or poorly to growth hormone therapy. No medications or other treatments are provided to the participants by Novo Nordisk as part of this study. The study will last for up to 1 year. The participants will attend their usual doctor's appointments. If the participants are not usually visiting the clinic, they will need to do it only once as part of this study. If the participant agrees to take part in the study, they will be asked to read and sign the 'Agreement to take part form'.
Primary Outcome
Measured as odds ratio.
Interventions
- OTHER No treatment is given
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2024-04-29 |
| Est. Completion | 2025-03-21 |
Why NCT05894876 stopped before completion
NCT05894876 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 43 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which No treatment is given is the first listed.
NCT05894876 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05894876 about?
NCT05894876 is a clinical study titled "A Study of the Genetic Basis of Response to Growth Hormone Treatment in Children With Idiopathic Short Stature". The study doctor will collect information from participants with Idiopathic Short Stature, who were treated with growth hormone for at least a year when they were children, before they reached puberty. The word "Idiopathic" refers to "unknown cause", and as such the study participants have/had short...
What is the current status of trial NCT05894876?
This trial is currently terminated. The enrollment target is 43 participants. The study started on 2024-04-29. Estimated completion is 2025-03-21.
What interventions are being tested in trial NCT05894876?
The interventions under investigation include: No treatment is given (OTHER).
Who is sponsoring clinical trial NCT05894876?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI